No definition available.
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
|
1. Apply sex-specific ruleonly females |
- |
2. Check conditions
|
- |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
3 out of 7 registries used, show all original rules. |
- |
4. Check minimum number of eventsNone |
- |
5. Include endpointsNone |
- |
6. Filter based on genotype QC (FinnGen only)None |
- |
Control definitions (FinnGen only)
- Control exclude
- C3_CANCER, C3_CANCER_WIDE
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF9
- Parent code in ICD-10
- D07
- Name in latin
- Carcinoma in situ prostatae
Similar endpoints
↥List of similar endpoints to
Carcinoma in situ of vagina
based on the number of shared cases.
Similar with more cases:
- Carcinoma in situ of vagina
- Carcinoma in situ of other and unspecified genital organs
- Carcinoma in situ of other and unspecified genital organs
- In situ neoplasms
- In situ neoplasms
Similar with less cases:
Case counts by codes
↥FinnGen case counts by registry codes:
No upset plot: script not run.
No upset table: script not run.
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 126 | 126 | - |
| Only index persons | 102 | 102 | - |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.00 | 0.00 | - |
| Only index persons | 0.00 | 0.00 | - |
| Median age at first event (years) | |||
| Whole population | - | 61.35 | - |
| Only index persons | - | 57.68 | - |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 147 | 147 | - |
| Unadjusted period prevalence (%) | 0.05 | 0.05 | - |
| Median age at first event (years) | 57.50 | 57.50 | - |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
No data
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 137
- Matched controls
- 1369
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
8077/2-C52.9
ICD-O-3
Squamous intraepithelial neoplasia, high grade of vagina, NOS
+∞
155.4
118
*
LEB00
NOMESCO Finland
Biopsy of vagina
861.4
130.1
109
6
ULA02
NOMESCO Finland
Kolposcopy
287.2
116.3
131
96
LEB30
NOMESCO Finland
Destruction of lesion of vaginal mucosa
2766.1
112.1
93
*
N89.2
ICD-10 Finland
Severe vaginal dysplasia, not elsewhere classified
+∞
84.3
72
*
XLD00
NOMESCO Finland
Sytologyspecimen from mouth of uterus
48.6
78.5
112
115
R87.6
ICD-10 Finland
Abnormal findings in specimens from female genital organs, abnormal cytological findings
37.8
70.6
104
105
N89.1
ICD-10 Finland
Moderate vaginal dysplasia
+∞
68.6
60
*
LDA20
NOMESCO Finland
Biopsy of vaginal cervix
32.9
58.6
82
59
LFB00
NOMESCO Finland
Biopsy of vulva or perineum
39.8
35.2
44
16
N89.0
ICD-10 Finland
Mild vaginal dysplasia
+∞
33.7
31
*
LDC03
NOMESCO Finland
Conisation of cervix uteri using diathermy or laser
18.4
32.1
52
44
LDA10
NOMESCO Finland
Curettage of cervix uteri
19.4
31.2
49
38
8077/2-C53.9
ICD-O-3
Squamous intraepithelial neoplasia, high grade of cervix uteri
55.5
23.4
27
6
N87.0
ICD-10 Finland
Mild cervical dysplasia
21.6
21.8
32
19
N90.2
ICD-10 Finland
Severe vulvar dysplasia, not elsewhere classified
245.8
21.2
21
*
N87.2
ICD-10 Finland
Severe cervical dysplasia, not elsewhere classified
18.2
18.1
28
19
LC2BE
NOMESCO Finland
Transvaginal ultrasound examination of uterus, parametria and lower abdomen
4.8
16.9
90
390
LEB10
NOMESCO Finland
Excision of lesion of vagina
68.5
16.2
18
*
D07.2
ICD-10 Finland
Carcinoma in situ: Vagina
+∞
14.9
14
*
H02AB02
ATC
dexamethasone; systemic
34.2
14.3
18
6
N90.1
ICD-10 Finland
Moderate vulvar dysplasia
+∞
12.7
12
*
115
Kela drug reimbursment
Breast cancer
+∞
12.7
12
*
LFB10
NOMESCO Finland
Excision of lesion of vulva or perineum
51.6
12.1
14
*
8077/2-C51.9
ICD-O-3
Squamous intraepithelial neoplasia, high grade of vulva, NOS
+∞
11.6
11
*
PJA12
NOMESCO Finland
Sentinel node biopsy
+∞
11.6
11
*
A63.0
ICD-10 Finland
Anogenital (venereal) warts
12.1
11.2
20
19
C50.41
ICD-10 Finland
Malignant tumor of the upper outer quadrant of the mammary gland, ductal tumor
+∞
10.5
10
*
WB103
NOMESCO Finland
Simple adjuvant cytostatic therapy
+∞
10.5
10
*
R87.5
ICD-10 Finland
Abnormal findings in specimens from female genital organs, abnormal microbiological findings
35.6
10.5
13
*
LDB20
NOMESCO Finland
Electrocoagulation or laser therapy of cervix uteri
25.7
10.5
14
6
WB113
NOMESCO Finland
Multiple adjuvant cytostatic therapy
+∞
9.5
9
*
HA003
NOMESCO Finland
Radiotherapy after partial ablation of mammary gland
+∞
9.5
9
*
D06BB10
ATC
imiquimod; topical
11.2
8.8
16
16
C44.31
ICD-10 Finland
Basocellular carcinoma of the skin on another or unspecified part of the face
+∞
8.4
8
*
N87.1
ICD-10 Finland
Moderate cervical dysplasia
8.9
7.9
16
20
WX105
NOMESCO Finland
Surface analgesia on skin or mucosa
4.5
7.8
28
74
N90.0
ICD-10 Finland
Mild vulvar dysplasia
26.7
7.7
10
*
ZXC10
NOMESCO Finland
Use of laser
14.5
7.5
12
9
A04AA55
ATC
palonosetron, combinations; systemic
+∞
7.4
7
*
C50.99
ICD-10 Finland
Breast, unspecified
+∞
7.4
7
*
8500/3-C50.9
ICD-O-3
Infiltrating duct carcinoma, NOS, of breast, NOS
+∞
7.4
7
*
128
Kela drug reimbursment
Cancers of female genital organs
+∞
7.4
7
*
8090/3-C44.9
ICD-O-3
Basal cell carcinoma, NOS, of skin, NOS
+∞
7.4
7
*
LFB20
NOMESCO Finland
Destruction of lesion of vulva or perineum
31.9
7.2
9
*
XX3DW
NOMESCO Finland
Time consuming IT work
6.5
7.2
18
31
HA1AE
NOMESCO Finland
Ultrasound examination of mammary glands
7.9
6.9
15
21
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
2.7
6.8
60
306
L02BG04
ATC
letrozole; oral
15.3
6.5
10
7
A04AA02
ATC
granisetron; systemic, transdermal
73.1
6.5
7
*
LFC00
NOMESCO Finland
Partial excision of vulva
73.1
6.5
7
*
HA1AA
NOMESCO Finland
X-ray mammography
6.9
6.4
15
24
L03AA14
ATC
lipegfilgrastim; parenteral
+∞
6.3
6
*
PJ5AN
NOMESCO Finland
Localisation of sentinell lymphnode with isotope imaging
+∞
6.3
6
*
PJD52
NOMESCO Finland
Block dissection of axillary lymph nodes
+∞
6.3
6
*
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
61
77
12.83
49.14
4.2
1.4
—
—
—
0
0
116
349
12.02
43.78
4.4
1.4
—
—
—
0
0
33
9
46.69
27.55
5.9
2.0
—
—
—
0
0
98
512
3.74
13.21
4.6
3.5
—
—
—
0
0
53
245
2.82
7.84
2.1
1.8
—
—
—
0
0
71
381
2.67
7.84
4.4
1.8
2.4
2.4
mmol/l
0.52
55
316
30
110
3.17
6.61
3.3
2.5
25.6
24.0
%
0.23
25
96
118
891
2.64
5.38
12.2
4.9
75.6
75.3
u/l
0.03
110
811
76
482
2.19
5.18
6.3
4.2
1.2
1.2
mmol/l
0.44
61
425
92
635
2.20
5.00
14.7
6.3
3.7
4.0
e9/l
0.89
84
551
71
449
2.12
4.77
7.3
3.2
35.9
36.5
g/l
0.46
64
416
33
153
2.49
4.63
2.1
1.7
—
—
—
0
0
31
140
2.54
4.59
1.7
1.8
—
—
—
0
0
21
79
2.93
4.38
2.6
1.5
21.7
31.0
u/ml
0.33
21
74
49
277
2.15
4.32
3.6
2.0
306.7
2979.5
umol/l
0.80
41
243
62
386
2.05
4.23
5.7
2.7
—
—
—
0
0
32
153
2.40
4.18
1.8
1.9
—
—
—
0
0
37
189
2.28
4.16
1.7
1.6
1149.6
1148.2
nmol/l
0.00
28
144
77
524
1.99
4.04
8.5
4.7
1.2
1.2
mmol/l
0.59
63
460
118
946
2.25
3.82
5.3
3.9
15.8
11.4
mm/h
1.68
105
862
78
542
1.94
3.77
2.8
2.3
79.3
80.2
nmol/l
0.11
65
479
8
12
6.98
3.72
1.1
1.1
—
—
—
0
0
9
19
4.97
3.29
2.1
1.2
—
—
—
0
0
9
19
4.97
3.29
2.1
1.2
—
—
—
0
0
61
412
1.82
3.06
3.3
3.1
25.2
18.5
ng/l
0.49
36
253
86
646
1.80
3.01
5.5
3.5
6.3
6.4
mmol/l
0.43
81
589
83
618
1.79
2.98
4.6
3.3
0.0
0.0
estimate
0.50
13
105
33
187
1.99
2.79
5.0
2.4
1.3
1.1
e6/l
0.08
19
96
82
616
1.75
2.79
6.3
4.6
0.0
0.0
estimate
0.50
12
103
21
100
2.28
2.75
2.5
1.7
—
—
—
0
0
16
68
2.52
2.66
1.3
1.3
—
—
—
0
0
46
297
1.80
2.61
5.2
2.6
0.3
0.5
e6/l
0.73
32
211
66
476
1.70
2.53
2.1
1.9
100.9
101.5
pmol/l
0.03
32
220
18
84
2.30
2.47
2.2
2.7
—
—
—
0
0
18
84
2.30
2.47
1.8
1.6
—
—
—
0
0
29
164
1.96
2.46
3.8
4.6
32.2
33.5
%
0.27
20
104
15
65
2.46
2.40
1.6
1.5
—
—
—
0
0
80
614
1.66
2.38
4.6
3.3
0.0
0.0
estimate
0.00
13
105
20
100
2.16
2.34
4.7
5.8
1.1
1.4
mmol/l
0.17
15
80
47
316
1.72
2.29
4.6
3.4
0.0
0.0
estimate
0.50
12
105
20
101
2.13
2.28
2.6
1.7
—
—
—
0
0
6
14
4.42
2.17
1.0
1.2
—
—
—
0
0
28
165
1.86
2.10
5.6
2.6
5.0
4.2
e6/l
0.14
14
76
6
16
3.86
1.95
1.7
1.6
—
—
—
0
0
10
40
2.61
1.88
1.5
2.3
2909.0
9201.5
u/l
—
5
16
132
1194
2.03
1.87
17.0
8.9
81.2
83.8
ml/min/173m2
0.58
106
957
26
158
1.78
1.77
4.7
4.9
—
—
—
0
0
62
475
1.53
1.70
5.0
3.2
—
—
—
0
0
136
1252
2.15
1.68
21.9
9.9
19.7
17.9
mg/l
0.29
104
917
39
274
1.58
1.56
3.5
2.9
1650.0
1020.4
ng/l
0.29
33
221
30
199
1.64
1.51
2.7
1.8
2.5
2.4
mmol/l
1.13
22
170
5
16
3.20
1.45
1.2
1.3
—
—
—
0
0
9
44
2.11
1.29
1.2
2.0
—
—
—
0
0
6
25
2.46
1.25
1.3
2.1
—
—
—
0
0
6
25
2.46
1.25
1.5
1.3
—
—
—
0
0
20
125
1.69
1.25
2.6
1.6
1.4
1.3
%
0.06
13
112
10
49
2.12
1.25
3.8
5.2
24.7
25.1
mmol/l
—
10
49
5
20
2.55
1.16
1.2
1.7
—
—
—
0
0
5
21
2.43
1.10
4.2
1.9
—
—
—
0
0
9
46
2.02
1.06
1.3
2.0
—
—
—
0
0
37
280
1.43
1.03
1.7
1.7
0.9
1.0
mg/l
0.14
28
213
10
54
1.91
0.99
1.5
1.5
—
—
—
0
0
35
267
1.41
0.93
1.6
1.4
22.8
23.6
nmol/l
0.11
28
227
6
29
2.11
0.90
1.3
1.2
—
—
—
0
0
6
30
2.04
0.88
1.0
1.1
—
—
—
0
0
8
45
1.82
0.86
11.3
2.0
—
—
—
0
0
36
281
1.37
0.84
1.6
1.5
—
—
—
0
0
13
82
1.64
0.81
1.4
1.4
—
—
—
0
0
0
26
0.00
0.79
0.0
1.6
—
—
—
0
0
6
34
1.80
0.77
1.0
1.6
—
—
—
0
0
5
27
1.88
0.69
1.4
1.3
—
—
—
0
0
92
838
1.26
0.65
4.3
2.8
78.8
38.0
u/l
0.70
83
787
39
321
1.29
0.64
1.3
1.3
0.8
2.1
u/ml
—
9
97
8
52
1.57
0.60
1.9
1.2
—
—
—
0
0
0
21
0.00
0.60
0.0
1.5
—
—
—
0
0
0
23
0.00
0.59
0.0
1.8
—
—
—
0
0
9
60
1.53
0.55
6.4
2.1
0.0
0.3
e6/l
—
9
55
32
384
0.79
0.53
1.9
1.6
1.2
1.4
mmol/l
1.03
21
335
5
31
1.63
0.43
1.0
1.5
—
—
—
0
0
5
31
1.63
0.43
1.0
1.5
—
—
—
0
0
5
31
1.63
0.43
1.4
1.8
—
—
—
0
0
5
31
1.63
0.43
1.0
1.5
—
—
—
0
0
5
31
1.63
0.43
1.2
1.2
—
—
—
0
0
0
16
0.00
0.41
0.0
1.1
—
—
—
0
0
0
18
0.00
0.40
0.0
1.1
—
—
—
0
0
0
18
0.00
0.40
0.0
1.1
—
—
—
0
0
0
19
0.00
0.39
0.0
1.2
—
—
—
0
0
0
19
0.00
0.39
0.0
1.2
—
—
—
0
0
128
1239
1.26
0.36
4.1
3.8
1.3
1.2
mmol/l
1.05
114
1156
120
1159
1.19
0.31
21.7
11.2
38.9
40.1
%
0.83
86
867
10
77
1.32
0.27
1.1
1.1
—
—
—
0
0
11
137
0.79
0.25
1.8
1.7
—
—
—
0
0
132
1292
1.21
0.23
4.7
4.3
1.6
1.6
mmol/l
0.29
116
1216
0
10
0.00
0.21
0.0
1.0
—
—
—
0
0
0
10
0.00
0.21
0.0
1.0
—
—
—
0
0
0
12
0.00
0.21
0.0
1.0
—
1.1
—
0
6
0
12
0.00
0.21
0.0
1.2
—
—
—
0
0
6
49
1.23
0.20
1.8
1.7
—
—
—
0
0
110
1071
1.11
0.17
4.7
4.2
14.6
14.5
pmol/l
0.14
96
989
132
1299
1.16
0.15
4.7
4.3
4.8
4.9
mmol/l
0.29
118
1222
31
288
1.10
0.13
1.3
1.3
1.2
10.9
u/ml
1.88
11
111
5
46
1.09
0.09
1.0
1.2
—
—
—
0
0
5
46
1.09
0.09
1.0
1.2
—
—
—
0
0
6
54
1.12
0.09
1.7
2.0
0.8
1.1
%
—
6
54
7
80
0.87
0.07
1.0
1.4
—
—
—
0
0
84
854
0.96
0.05
3.3
3.2
—
—
—
0
0
11
120
0.91
0.05
3.2
1.7
320.0
361.3
nmol/l
0.29
11
110
133
1321
1.07
0.03
5.4
4.8
2.8
2.9
mmol/l
0.27
118
1239
127
1279
0.95
0.03
4.9
4.3
5.7
5.8
mmol/l
0.06
115
1184
123
1239
0.96
0.03
5.5
5.0
1.7
1.8
mu/l
1.14
108
1152
30
291
1.04
0.02
1.3
1.3
18.2
38.9
iu/ml
—
10
95
119
1189
1.00
0.00
6.1
5.3
38.6
39.0
mmol/mol
0.15
104
1116
0
8
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
0.00
0.0
1.8
—
—
—
0
0
0
6
0.00
0.00
0.0
1.3
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
8
0.00
0.00
0.0
1.0
—
—
—
0
0
12
120
1.00
0.00
1.3
1.3
44.0
141.4
iu/ml
—
5
56
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
0
8
0.00
0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.7
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
5
58
0.86
0.00
1.0
1.5
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
0.00
0.0
1.4
—
—
—
0
0
0
8
0.00
0.00
0.0
1.4
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
0.00
0.0
1.5
—
—
—
0
0
0
8
0.00
0.00
0.0
1.1
—
10.2
—
0
8
0
5
0.00
0.00
0.0
1.6
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint CD2_INSITU_VAGINA_EXALLC and mortality.
Females
No dataMales
No dataMortality risk
Mortality risk for people of age
years, who have CD2_INSITU_VAGINA_EXALLC.| N-year risk | Females | Males |
|---|---|---|
| 1 | No data | No data |
| 5 | No data | No data |
| 10 | No data | No data |
| 15 | No data | No data |
| 20 | No data | No data |
Relationships between endpoints
↥Index endpoint: CD2_INSITU_VAGINA_EXALLC – Carcinoma in situ of vagina
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data